
WEDNESDAY, Aug. 7, 2024 (HealthDay news) — Medicare and Medicaid patients are less likely to get cutting-edge weight-loss drugs than people with private insurance are, a new study finds. Medicaid accounted for less than 10% of semaglutide (Ozempic, Wegovy) prescription fills in 2023, researchers found. Similarly, Medicare Part D accounted for less than 29% of… read on > read on >